Cadrenal Therapeutics, INC. (CVKD) — 10-K Filings

All 10-K filings from Cadrenal Therapeutics, INC.. Browse 3 Annual Report reports with AI-powered summaries and risk analysis.

10-K Filings (3)

Cadrenal Pivots to CAD-1005, Eyes Phase 3 for Deadly Blood Disorder — Mar 31, 2026 Risk: high
Cadrenal Therapeutics, Inc. (CVKD) reported a strategic shift in its primary focus to the development of CAD-1005 for immune-mediated and thrombotic disorders,
Cadrenal Therapeutics Files 2024 Annual Report — Mar 13, 2025 Risk: medium
Cadrenal Therapeutics, Inc. filed its annual report for the fiscal year ended December 31, 2024. The company, incorporated in Delaware and headquartered in Pont
Cadrenal Therapeutics Files 2023 Annual Report on Form 10-K — Mar 11, 2024 Risk: low
Cadrenal Therapeutics, Inc. (CVKD) filed a Annual Report (10-K) with the SEC on March 11, 2024. Cadrenal Therapeutics, Inc. filed its annual report on Form 10-K

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX